Shaosen Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shaosen Zhang has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Chen Wu
Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
40 shared publications - Dongxin Lin
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China; Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China
33 shared publications - Jiang Chang
Department of Health Toxicology, Key Laboratory for Environment and Health, School of Public Health, Tongji Medical College Huazhong University of Science and Technology Wuhan China
27 shared publications - Xinjie Chen
Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) 1 Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital Beijing, China
26 shared publications - Guoyu Cheng
Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) 1 Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital Beijing, China
25 shared publications - Liang Zhu
Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) 1 Department of Etiology and Carcinogenesis, National Cancer Center/National Clinical Research Center/Cancer Hospital Beijing, China
25 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- p. e0177126
Baicalin and levofloxacin exert divergent modulation on gut microbiota and metabolome crosstalk in DSS-triggered ulcerative colitis
Baicalin (BA), a bioactive flavonoid, and levofloxacin hydrochloride (LH), a fluoroquinolone antibiotic, both hold potential for ulcerative colitis (UC) treatment, yet the mechanistic differences in their regulation of gut microbiota and metabolome remain elusive. This study aimed to systematically compare their therapeutic efficacy and underlying mechanisms in a dextran sulfate sodium-induced murine colitis model, with a focus on gut microbial and metabolic modulation. Mice were randomized into Control, model, BA-treated, and LH-treated groups. Disease severity was assessed via body weight changes, disease activity index, colon length, and histopathological analysis. Western blot and enzyme-linked immunosorbent assay were employed to detect NF-κB pathway activation and pro-inflammatory cytokine levels, while 16S rRNA sequencing and metabolomics profiled gut microbiota and metabolites. Both agents markedly ameliorated colitis symptoms, suppressed NF-κB activation, and cytokine expression, with BA showing superior cytokine inhibition. BA enriched beneficial Lactobacillus , regulating isoflavone/alkaloid synthesis; LH elevated Akkermansia abundance and modulated amino acid metabolism. These findings reveal distinct therapeutic mechanisms of BA and LH, laying a foundation for personalized UC therapy and validating BA’s traditional medicinal utility. IMPORTANCE: Ulcerative colitis remains a prevalent inflammatory bowel disease with limited microbiota-targeted therapies. Baicalin and levofloxacin both alleviate dextran sulfate sodium-induced colitis, yet their gut microbiome and metabolome regulatory mechanisms have not been directly compared. This study demonstrates that baicalin and levofloxacin exert anti-colitis effects via divergent microbiota-metabolite axes: baicalin enriches Lactobacillus and modulates isoflavone/alkaloid metabolism, while levofloxacin increases Akkermansia and reshapes amino acid metabolism. These distinct mechanisms provide new evidence for developing microbiota-based personalized strategies for ulcerative colitis treatment.
- 23 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- p. e0177126
Open AccessBaicalin and levofloxacin exert divergent modulation on gut microbiota and metabolome crosstalk in DSS-triggered ulcerative colitis
Baicalin (BA), a bioactive flavonoid, and levofloxacin hydrochloride (LH), a fluoroquinolone antibiotic, both hold potential for ulcerative colitis (UC) treatment, yet the mechanistic differences in their regulation of gut microbiota and metabolome remain elusive. This study aimed to systematically compare their therapeutic efficacy and underlying mechanisms in a dextran sulfate sodium-induced murine colitis model, with a focus on gut microbial and metabolic modulation. Mice were randomized into Control, model, BA-treated, and LH-treated groups. Disease severity was assessed via body weight changes, disease activity index, colon length, and histopathological analysis. Western blot and enzyme-linked immunosorbent assay were employed to detect NF-κB pathway activation and pro-inflammatory cytokine levels, while 16S rRNA sequencing and metabolomics profiled gut microbiota and metabolites. Both agents markedly ameliorated colitis symptoms, suppressed NF-κB activation, and cytokine expression, with BA showing superior cytokine inhibition. BA enriched beneficial Lactobacillus , regulating isoflavone/alkaloid synthesis; LH elevated Akkermansia abundance and modulated amino acid metabolism. These findings reveal distinct therapeutic mechanisms of BA and LH, laying a foundation for personalized UC therapy and validating BA’s traditional medicinal utility. IMPORTANCE: Ulcerative colitis remains a prevalent inflammatory bowel disease with limited microbiota-targeted therapies. Baicalin and levofloxacin both alleviate dextran sulfate sodium-induced colitis, yet their gut microbiome and metabolome regulatory mechanisms have not been directly compared. This study demonstrates that baicalin and levofloxacin exert anti-colitis effects via divergent microbiota-metabolite axes: baicalin enriches Lactobacillus and modulates isoflavone/alkaloid metabolism, while levofloxacin increases Akkermansia and reshapes amino acid metabolism. These distinct mechanisms provide new evidence for developing microbiota-based personalized strategies for ulcerative colitis treatment.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S11. Gating strategies for flow cytometry analysis
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S11. Gating strategies for flow cytometry analysis
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S9. Characterization of predictive biomarkers in the retrospective and prospective cohorts
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S9. Characterization of predictive biomarkers in the retrospective and prospective cohorts
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S2. Detailed plasma sampling time points in the longitudinal analysis cohorts
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S2. Detailed plasma sampling time points in the longitudinal analysis cohorts
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S3. The clinicopathologic information of treatment-naïve ESCC patients
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S3. The clinicopathologic information of treatment-naïve ESCC patients
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S5. SOX2 is the key transcriptional regulator of GPNMB in ESCC
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S5. SOX2 is the key transcriptional regulator of GPNMB in ESCC
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S4. Differentially expressed plasma proteins between non-responders (NR) and responders (R) identified by proteomic analysis
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Table S4. Differentially expressed plasma proteins between non-responders (NR) and responders (R) identified by proteomic analysis
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S4. Tumor-derived soluble GPNMB is the critical mediator of CD8⁺ T cell exhaustion and immune evasion
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S4. Tumor-derived soluble GPNMB is the critical mediator of CD8⁺ T cell exhaustion and immune evasion
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S3. GPNMB induces CD8⁺ T cell exhaustion via SDC4-CD148 axis and suppresses anti-tumor immunity in vivo
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S3. GPNMB induces CD8⁺ T cell exhaustion via SDC4-CD148 axis and suppresses anti-tumor immunity in vivo
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S1. GPNMB is upregulated in ESCC and associated with immunotherapy resistance
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Circulating GPNMB-Based Multimodal Model Integrates Tumor−Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer
Supplementary Figure S1. GPNMB is upregulated in ESCC and associated with immunotherapy resistance